rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

electroCore, Inc.

ECOR · Nasdaq

Health CareMedical DevicesJust dropped out

ECOR stood above a rising 150-day average in 28 of the last 52 weekly readings, and has been out of that trend for the last 1 week. It is 5.1% below that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−7 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Just dropped out
Weeks in an uptrend
out for 1
Industry in uptrend
27% -7 in 4 wk
Insider buys, 12 months
$419K
Insider sales, 12 months
$1.9M
Officials’ trades on record
0
Institutions holding
32 (+3)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 28 of 52 weeks.

20 Apr – 19 Oct
19%29%40%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1.2M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months5
Sale orders, 12 months9
Buyers · sellers3 · 2
WhoDidSharesTraded
Thomas J. ErricoDirectorbought5,000at $9.8214 Sep 2026filed 22 Sep 2026
Michael FoxOfficerbought5,000at $9.8011 Sep 2026filed 18 Sep 2026
Joshua S. LevCFO and Interim Presidentsold3,000at $9.3625 Aug 2026filed 25 Aug 2026
Joshua S. LevCFO and Interim Presidentsold5,000at $9.8824 Aug 2026filed 25 Aug 2026
Joshua S. LevCFO and Interim Presidentsold12,000at $10.2221 Aug 2026filed 25 Aug 2026
Thomas J. ErricoDirectorbought5,000at $9.8513 Aug 2026filed 17 Aug 2026
Joshua S. LevCFO and Interim Presidentsold6,667at $9.0028 May 2026filed 29 May 2026
Joshua S. LevCFO and Interim Presidentsold3,000at $6.5022 May 2026filed 22 May 2026
Thomas J. ErricoDirectorbought9,992at $5.9921 May 2026filed 26 May 2026
Daniel S. GoldbergerOthersold80,000at $6.8023 Apr 2026filed 12 Jun 2026
Daniel S. GoldbergerOthersold16,072at $6.0210 Apr 2026filed 14 Apr 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders32+3 on the quarter
New · exited9 · 6
Reported value$8.9M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026211,639$1.8M+8,995+4.4%
FourWorld Capital Management LLCnew · filed 14 Aug 202694,000$812K+94,000
WEXFORD CAPITAL LPnew · filed 14 Aug 202692,060$795K+92,060
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 202673,149$632K-4,934−6.3%
NORTHERN TRUST CORPadded · filed 13 Aug 202666,506$575K+55,389+498.2%
JANE STREET GROUP, LLCnew · filed 14 Aug 202663,402$548K+63,402
Wealthspire Advisors, LLCunchanged · filed 11 Aug 202647,498$410K00.0%
CITADEL ADVISORS LLCnew · filed 14 Aug 202643,803$378K+43,803
MARSHALL WACE, LLPnew · filed 13 Aug 202643,672$377K+43,672
VANGUARD FIDUCIARY TRUST COadded · filed 13 Aug 202638,770$335K+242+0.6%
31 Mar 2023 – 30 Jun 2026
182532Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Thomas J. Errico Company insiderDirector · last 14 Sep 202617 · 0
Michael Fox Company insiderOfficer · last 11 Sep 20261 · 0
Elena Bonfiglioli Company insiderDirector · last 9 Sep 20260 · 0
James Charles Theofilos Company insiderDirector · last 9 Sep 20260 · 0
John P. Gandolfo Company insiderDirector · last 9 Sep 20264 · 0
Julie Ann Goldstein Company insiderDirector · last 9 Sep 20260 · 0
Patricia Wilber Company insiderDirector · last 9 Sep 20260 · 0
Joshua S. Lev Company insiderOfficer · last 8 Sep 20260 · 7
Daniel S. Goldberger Company insiderOther · last 23 Apr 202621 · 2
Thomas M. Patton Company insiderDirector · last 2 Sep 20250 · 0
Charles Steve Theofilos Company insiderDirector · last 3 Sep 20240 · 0
F. Peter Cuneo Company insiderDirector · last 3 Sep 20240 · 0

Same industry

RCEL Avita MedicalLeading+100%
HAE HaemoneticsLeading+48%
ATRC AtriCureLeading+47%
HTFL HeartflowLeading+47%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202586.8%
Operating profit marginFY 2025 · to 31 Dec 2025-41.1%
Free cash flow marginFY 2025 · to 31 Dec 2025-25.8%
Return on capital employedFY 2025 · to 31 Dec 2025-180%
Share count trendFY 2025 · to 13 Mar 20261.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$7.0M
Free cash flowFY 2025 · to 31 Dec 2025−$8.3M

Analyst forecasts

No analyst forecasts yet.